Skip to main content
. 2021 Mar 22;13(6):1438. doi: 10.3390/cancers13061438

Figure 4.

Figure 4

6-SFN + JQ1 co-treatment downregulates ERCC2 in human colon cancer cells. (A) ERCC2 expression analyzed by RT-qPCR in tumor (SW480, HCT116) and normal (CCD841) cells, and (B) treatment of HCT116 cells with drugs for 48 h; ** p < 0.01, *** p < 0.001. (C) Immunoblot analysis of cell lysates treated as in B; β-Actin, loading control. (D,E) Viability of CCD841 normal, HCT116, HCT116 p21−/−, and HCT116 p53−/− cells treated with 6-SFN or JQ1 over a range of concentrations for 48 h. Mean ± SE; n = 3 biological replicates.